S E Karp
Overview
Explore the profile of S E Karp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Satagopan J, Offit K, Foulkes W, Robson M, Wacholder S, Eng C, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 May;
10(5):467-73.
PMID: 11352856
Several studies using families with multiple occurrences of breast cancer have provided evidence for a very high lifetime penetrance in carriers of BRCA1 or BRCA2 mutations. However, there are reasons...
2.
Latosinsky S, Cornell D, Bear H, Karp S, Little S, Paredes E
Breast Cancer Res Treat
. 2000 Aug;
60(3):277-83.
PMID: 10930116
Stereotactic core needle biopsy (SCNB) has become a popular method for diagnosis of occult breast abnormalities. There are few large series of SCNB from a single institution. Data on patients...
3.
Karp S
Semin Surg Oncol
. 2000 May;
18(4):296-304.
PMID: 10805951
The recent discovery of the breast cancer-associated genes BRCA1 and BRCA2 has changed the clinical care provided to women at high risk of breast cancer. We will review what is...
4.
Katabi M, Chan H, Karp S, Batist G
Hum Gene Ther
. 1999 Feb;
10(2):155-64.
PMID: 10022541
The use of tissue- or tumor-selective promoters in targeted gene therapy for cancer depends on strong and selective activity. Hexokinase type II (HK II) catalyzes the first committed step of...
5.
Foulkes W, Wong N, Brunet J, Begin L, Zhang J, Martinez J, et al.
Clin Cancer Res
. 1998 Nov;
3(12 Pt 1):2465-9.
PMID: 9815648
Germ-line mutations in BRCA1 confer an increased risk of developing breast and ovarian cancer, but little is known about the clinical course of breast cancer in BRCA1 mutation carriers compared...
6.
Karp S
J Immunother
. 1998 Feb;
21(1):56-61.
PMID: 9456437
High-dose therapy with interleukin-2 (IL-2) can produce significant responses in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Several studies have shown the benefit of low-dose IL-2 in...
7.
Karp S, Tonin P, Begin L, Martinez J, Zhang J, Pollak M, et al.
Cancer
. 1997 Aug;
80(3):435-41.
PMID: 9241077
Background: In the Ashkenazim, three recurrent germline mutations have been identified in the breast carcinoma susceptibility genes BRCA1 and BRCA2: 185delAG, 5382insC (BRCA1), and 6174delT (BRCA2). The frequency of these...
8.
Sadeghi N, Black M, Hier M, Shenouda G, Karp S
Arch Otolaryngol Head Neck Surg
. 1997 Jan;
123(1):25-30.
PMID: 9006500
Objectives: To study immunotherapy for advanced head and neck squamous cell carcinoma using AT-84, a spontaneously arising murine tumor. We examined the draining lymph nodes (DLNs) for generation of potential...
9.
Hier M, Black M, Shenouda G, Sadeghi N, Karp S
Laryngoscope
. 1995 Oct;
105(10):1077-80.
PMID: 7564839
A murine model for the immunotherapy of head and neck cancer was established. The AT-84 tumor, a spontaneously arising oral squamous cell tumor of C3H mice, was evaluated for susceptibility...
10.
Shiloni E, Karp S, Custer M, Shilyansky J, Restifo N, Rosenberg S, et al.
Cancer Immunol Immunother
. 1993 Oct;
37(5):286-92.
PMID: 8402732
Gene modification of tumor cells with the cDNA for interferon gamma (IFN gamma) has been shown to increase the immunogenicity of some tumor cells. In order to explore further the...